ASND vs. TAK: Ascendis Pharma vs. Takeda Pharmaceutical Stock Comparison

Company Profile

Ascendis Pharma (ASND) and Takeda Pharmaceutical (TAK) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but ASND is classified in Biotechnology while TAK is classified in Pharmaceuticals.

Ascendis Pharma (ASND) trades as ordinary local shares, while Takeda Pharmaceutical (TAK) trades as an ADR — compare with FX exposure, depositary-program fees, and dividend-withholding-tax differences in mind.

Price Performance

Cumulative Growth

Trailing Returns

Calendar-Year Returns

Performance Metrics

Risk Profile

Drawdown History

Return Distribution

Risk Metrics

Takeda Pharmaceutical (TAK) reports a negative beta of -0.01, suggesting inverse market sensitivity over the measurement window. That is uncommon for ordinary equities and can reflect commodity-linked or hedge-like exposure, but it can also come from statistical noise. Ascendis Pharma (ASND) has a non-negative beta of 0.38.

Risk-Adjusted Performance

Risk-Return Positioning

Risk-Adjusted Metrics

Profitability

Ascendis Pharma (ASND) at 118.78% clears its industry range for ROE, a sharper capital-efficiency signal than Takeda Pharmaceutical (TAK) at 0.56%, which is closer to a typical peer reading.

Ascendis Pharma (ASND) at 70.85% converts revenue to bottom-line profit above its industry’s benchmark range, while Takeda Pharmaceutical (TAK) at 0.87% keeps roughly the typical share for its industry.

Both Ascendis Pharma (ASND) at 64.98% and Takeda Pharmaceutical (TAK) at 24.55% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.

Profitability Metrics

Growth

Ascendis Pharma (ASND) at 98.03% sits in the top revenue growth quartile, while Takeda Pharmaceutical (TAK) at -1.66% is in the bottom quartile, showing a clear gap in revenue momentum.

Only one side can be read here: Takeda Pharmaceutical (TAK) reports EPS growth of 77.96%, ranked against its industry; Ascendis Pharma (ASND) has no EPS growth figure this period.

Growth Metrics

Financial Strength

Ascendis Pharma (ASND) at 2.99 keeps current ratio within its industry’s typical mid-range, while Takeda Pharmaceutical (TAK) at 1.15 runs in the tighter-liquidity quartile — a thinner cushion against current liabilities for TAK.

Ascendis Pharma (ASND) at 0.31 carries an industry-typical debt-to-equity mix, while Takeda Pharmaceutical (TAK) at 0.72 uses more debt funding than most peers.

Financial Strength Metrics

Dividends

Ascendis Pharma (ASND) pays no dividend (yield 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Takeda Pharmaceutical (TAK) reports a yield of 953.28%, ranking against industry peers normally.

Takeda Pharmaceutical (TAK) reports payout ratio above 100% at 426.53%, meaning dividends exceeded current-period earnings; Ascendis Pharma (ASND) pays no dividend (payout 0.00%).

Dividend Metrics

Valuation

Ascendis Pharma (ASND) at 19.68 is near its industry’s usual P/E ratio, while Takeda Pharmaceutical (TAK) at 300.29 sits above its peer range — an unusually expensive price for TAK’s trailing earnings.

Takeda Pharmaceutical (TAK) at 0.01 sits in the cheaper P/S ratio quartile while Ascendis Pharma (ASND) at 16.14 prices around its industry’s middle — TAK costs less per dollar of sales, though read it alongside growth and margins.

Takeda Pharmaceutical (TAK) at 1.43 looks cheap against book in the lower P/B ratio quartile, while Ascendis Pharma (ASND) at 10.45 carries a premium in the upper quartile — a clear price-to-book gap.

Valuation Metrics